Clinical Trials Logo

Chronic Obstructive Pulmonary Disease clinical trials

View clinical trials related to Chronic Obstructive Pulmonary Disease.

Filter by:

NCT ID: NCT02487394 Terminated - Asthma Clinical Trials

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

Proteomics
Start date: May 2014
Phase:
Study type: Observational [Patient Registry]

The purpose of the study is to better understand proteomics of asthma and COPD, and response to therapy. There are two Phases to this study broken into two arms. In Phase I, we propose is to use discovery proteomics and techniques to identify protein expression signatures. Subjects who complete Phase I are eligible, but not required, to enroll in Phase II. In Phase II, we propose to establish and validate the predictive value of protein signatures for treatment responses using inhaled corticosteroids.

NCT ID: NCT02479841 Completed - Quality of Life Clinical Trials

Health-promoting Competence, Coping and Quality of Life in Patients With COPD

REKV-13/1741
Start date: February 2015
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and disability, and by 2020, it is expected to be the third leading cause of mortality worldwide. COPD is a major public health concern and has considerable impact on health and quality of life. For this study an evidence based self-management program is developed, the purpose of the study is to see if this self-management program, in collaboration between specialized health services and municipality health services, improves patients with COPD health-promoting competence, coping and quality of life, and reduces health service costs.The study has a RCT design.

NCT ID: NCT02478359 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Walk On! Physical Activity Coaching

Start date: June 2015
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is the third leading cause of the death in the US. The personal, social and economic costs of the disease are tremendous, with annual expenditures of nearly $50 billion, mostly from hospitalizations for exacerbations of COPD and associated sequelae. For the vast majority of patients, despite optimal pharmacological therapy, living with COPD is characterized by unrelieved dyspnea, physical inactivity, deconditioning, and an insidious downward spiral of social isolation and depression that has a profound impact on the lives of patients and their caregivers. There is mounting evidence that physical inactivity is significantly associated with more frequent hospitalizations and increased mortality in COPD even after adjusting for disease severity. While practice guidelines recommend regular physical activity for all patients with COPD, health systems are challenged in operationalizing an effective and sustainable approach to assist patients in being physically active. The investigators propose a pragmatic randomized controlled trial to determine the effectiveness of a 12-month physical activity coaching intervention (Walk On!) compared to standard care for 1,650 COPD patients from a large integrated health care system.

NCT ID: NCT02477397 Active, not recruiting - COPD Clinical Trials

Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

Start date: May 1, 2015
Phase: Phase 3
Study type: Interventional

Study to investigate the effects of symptom-driven maintenance and reliever therapy in COPD.

NCT ID: NCT02474017 Completed - Asthma Clinical Trials

An Open Study to Assess the Robustness of the CRC749 Inhaler

Start date: May 2015
Phase: Phase 1
Study type: Interventional

To confirm the robustness of the CRC749 inhaler.

NCT ID: NCT02473237 Completed - COPD Clinical Trials

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)

EMERAL
Start date: April 2013
Phase: Phase 4
Study type: Interventional

Chronic Obstructive Pulmonary Disease (COPD) secondary to biomass exposure constitutes a chronic respiratory condition frequently excluded from large clinical trials. Biomass exposure COPD have some histopathologic, clinical, radiological and functional differences with tobacco smoke COPD. However, until now, there are no evidence in this patients about the clinical response to bronchodilators routinely used in tobacco smoke COPD. Primary objective: To compare changes in walked meters from baseline on six minute walking test (6MWT) to 23:45 hours after one dose of indacaterol vs tiotropium in patients with moderate to severe COPD secondary to biomass exposure. Secondary objectives: To compare changes in pulmonary function (inspiratory capacity, Forced Expiratory Volume in first second (FEV1) milliliters, FEV1 "through") from baseline (-10 minutes) to 23:45 hours after one dose of indacaterol vs tiotropium in patients with moderate to severe COPD secondary to biomass exposure. This will be an open label study, double blinded, cross over and conducted at specialized respiratory care center (National Institute of Respiratory Diseases), to compare the acute effects of ultra long acting bronchodilators used in tobacco smoke exposure COPD. Unicentric study. Ethics Committee approbation: C 22-12

NCT ID: NCT02471235 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Short-course Out-patient Pulmonary Rehabilitation and COPD Exacerbations

Start date: July 2015
Phase: N/A
Study type: Interventional

This study assessed whether a short course pulmonary rehabilitation programme with periodic reinforcement exercise training and phone call reminders would help to increase physical activity in COPD patients and also decrease readmissions for AECOPD.

NCT ID: NCT02468635 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Rehabilitation of Patients With Lung Chronic Obstructive Pulmonary Disease

PR
Start date: June 2015
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is characterized by the obstruction is not fully reversible airway, where the severity of the disease and the prognosis is not determined solely by changes in lung function. Pulmonary rehabilitation is a multidisciplinary program of care for patients with chronic respiratory diseases, individually designed to optimize physical and social performance and autonomy of these patients, promoting improvement in functional exercise capacity, quality of life, reducing dyspnea, frequency and duration of hospitalizations and reduce the frequency of exacerbations of the disease. The overall objective of the research is to evaluate the effects of pulmonary rehabilitation program on exercise capacity, lung function, quality of daily life and reduction of dyspnea in patients with COPD. A study type randomized, open-label trial following the recommendations of the CONSORT (Consolidated Standards of Reporting Trials) will be held. The study will be conducted at the Clinic Physiotherapy Course of the School with a sample of 58 patients. The intervention will be performed sessions three times a week for 16 weeks (8 weeks for assessment and 8 weeks for adaptation and (pulmonary rehabilitation training). The PR (pulmonary rehabilitation) will last 60-120 minutes each.O group A (control) will receive treatment of traditional pulmonary rehabilitation and without resistive training for upper limb (UL) and group B will receive the same treatment control with additional training of upper limb strength.

NCT ID: NCT02467452 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Start date: May 2015
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate the triple combination of beclometasone dipropionate + formoterol fumarate + glycopyrronium bromide is effective in term of quality of life in COPD patients (Chronic Obstructive Pulmonary Disease).

NCT ID: NCT02466503 Completed - Asthma Clinical Trials

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The objective of this pivotal study is to evaluate the relative bioavailability of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in healthy volunteers with charcoal block.